Related Experiment Video
Updated: May 29, 2025

Chronic Salmonella Infection Induced Intestinal Fibrosis
Published on: September 22, 2019
Predictors for Chronic Opioid Use in Patients With Inflammatory Bowel Disease: A Population-Based Cohort Study
Bente Mertz Nørgård1,2, Caroline Thingholm Thorarinsson1,2, Jan Nielsen1,2
1Center for Clinical Epidemiology, Odense University Hospital, Odense C, Denmark.
Introduction:
A significant proportion of patients with Crohn's disease (CD) and ulcerative colitis (UC) become opioid users, but data pertaining to predictors of chronic opioid use remain sparse. We examined predictors for chronic opioid use in CD/UC.
Methods:
This is a nationwide cohort study based on Danish registries, comprising incident patients with CD/UC (≥ 18 years) from January 1, 1996, to December 31, 2021. Chronic opioid use was defined as ≥ 1 prescriptions in at least 2 of 3 consecutive quarters. Cox regression models were used to estimate adjusted hazard ratios for predictors for chronic opioid use. Several variables and time-varying covariates (inflammatory bowel disease surgery, inflammatory bowel disease, and psychotropic medications) were included.
Results:
In 15,092 patients with CD, 4,141 (27.4%) became chronic opioid users (median follow-up 7.35 years, 25%-75% percentiles [interquartile range] 3.40-13.66 years). The 3 most important predictors were surgery (4.20, 95% confidence interval [CI] 3.72-4.75), hypnotics/sedatives (2.02, 95% CI 1.81-2.25), and age ≥ 50 years (1.92, 95% CI 1.77-2.09). In 30,416 patients with UC, 6,777 (22.3%) became chronic users (median follow-up 8.80 years, interquartile range 4.20-15.22 years). The 3 most important predictors were surgery (4.81, 95% CI 4.20-5.52), age ≥ 50 years (2.62, 95% CI 2.44-2.82), and hypnotics/sedatives (2.11, 95% CI 1.95-2.29).
Discussion:
An alarming proportion of patients became chronic opioid users. These results are helpful to risk stratify patients to prevent chronic opioid use. Clinicians should be particularly attentive in patients who have had surgery, who use hypnotics/sedatives, and who are elderly. We need evidence regarding pain management strategies, efficacy of nonopioid analgesics, and opioid cessation strategies.
Related Concept Videos
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

